$HLF

Herbalife earnings beat by $0.02, revenue topped estimates

Herbalife (HLF) reported Q3 EPS of $0.64, beating estimates by $0.02, with revenue of $1.35B, exceeding expectations. The stock is up 15.38% in 3 months and 64.56% in 12 months. InvestingPro rates its financial health as 'good performance'.

Original reporting
Published Nov 2, 2026, 9:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$HLF
Bullish
high confidence
Mentioned
$HLF
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HLFBullishHigh
01

Why it matters

The earnings beat may trigger buying pressure, but lack of forward guidance leaves uncertainty.

02

Market read

Earnings beat for a mid‑cap consumer company, likely to influence short‑term price action.

03

What to watch

Guidance outlook and margin trends were not disclosed, which could temper the rally.

Relevance 8/10Novelty 8/10Timing: post‑market today

Background

Herbalife (NYSE: HLF) posted Q3 results that beat analyst expectations on both earnings per share and revenue.

Company-level read

Ticker impact

$HLFBullishHigh confidence
Context

Herbalife reported Q3 EPS of $0.64 beating estimates and revenue of $1.35B above consensus.

Expected impact

likely upward pressure as the market prices in the earnings beat

Evidence & confidence

The beat is a fresh primary disclosure with material revenue, prompting short‑term buying interest.

Market effects

May lift other nutrition and weight‑loss companies as the sector benefits from a strong earnings trend.

Positive for US consumer‑services stocks.

Limited to investors tracking mid‑cap consumer stocks.

Counterpoint

If the beat is already priced in, the stock could face short‑term profit‑taking.

Key entities

  • Herbalife

    Nutrition and weight‑loss products provider.

Related articles

$HLFMedAI 8/10

Herbalife Ltd (HLF) (Q3 2026) Earnings Call Highlights: Fifth Straight Quarter

Herbalife (HLF) reported Q3 2026 net sales of $1.4B, up 6% YoY, and adjusted EBITDA of $182M, beating guidance. Growth was driven by India and nutrition clubs, while EMEA and China saw declines. The company raised full-year sales guidance but expects gradual margin expansion. Interim CEO John DeSimone discussed product repositioning and new technology platforms. Operating cash flow rose 27% YoY, and net leverage improved to 2.0x.

$HLFHighAI 8/10

Why Herbalife Stock Is Up Today

Herbalife (HLF) shares rose 8% after Q3 results showed 6% revenue growth to $1.35B, with Asia Pacific up 18%. Adjusted net income increased 33% to $68.5M. The company raised full-year sales guidance and announced a $250M stock buyback program. According to interim CEO John DeSimone, growth is driven by 3M+ independent distributors.

$HLFMedAI 8/10

Herbalife Reports Q3 2026 Financial Results

Herbalife Ltd. reported Q3 2026 net sales of $1.35B, up 6% YoY, with regional growth varying. Adjusted EBITDA was $182.4M, EPS $0.55. Gross margin slightly declined to 77.3%. The company cited refinancing benefits and debt reduction. Management expects continued net sales growth.

$HLFHighAI 8/10

Herbalife (HLF) Q3 2026 Earnings Call Transcript

Herbalife (HLF) reported Q3 2026 net sales of $1.4B, up 6% YoY, and adjusted EBITDA of $182M, exceeding guidance. Interim CEO John DeSimone highlighted growth opportunities, including strengthening Nutrition Clubs and expanding the Bioniq brand. The company aims to enhance distributor support and technology capabilities.

$HLFMedAI 8/10

What Herbalife (HLF) Said on Its Q3 Earnings Call

Herbalife (HLF) reported Q3 sales growth of 5.1% in constant currency and 9% reported, with North America up 1.7%. FX reduced net sales by $21M. The company outlined priorities: nutrition clubs, tech platforms, and Bioniq brand growth. It expects Q4 sales growth of 0.5% to 4.5% and raised full-year sales guidance to 4.9% to 5.9%. Operating cash flow rose 27% YoY to $298M.